Lauren Mateja, Managing Editor

Kristian Reich, MD, PhD, discussed a therapeutic breakthrough with bimekizumab, a novel biologic in development that inhibits IL-17F in addition to IL-17A.

The Dermatologist spoke with investigators behind two prominent international registries dedicated to better understanding how concomitant psoriasis and COVID-19 can affect patient care and outcomes now and in the future.

A National Rosacea Society expert roundtable discussed the need to address persistent facial erythema in patients with rosacea through research and management options.

Though many in-person meetings have put a pause on education in 2020, the Interdisciplinary Autoimmune Summit is forging the way with a new virtual format from July 10 to 12.

Coronavirus disease, or COVID-19, may still be novel to the dermatology community, but research since its initial appearance in humans have elucidated some of the mystery around the virology and epidemiology of SARS-CoV-2.

The Centers for Disease Control and Prevention and World Health Organization advise that hand washing is critical to slowing the spread of infection, but patients with dermatitis may need further guidance from their dermatologists.

Patients with psoriasis and psoriatic arthritis have increased calls to their dermatologist for advice on continuance of their therapy during uncertain times. Guidance from national organizations provide answers that dermatologists can pass on to their patients.

The number of therapeutic options for rosacea management has expanded, but these treatments can only help patients who have been diagnosed. Rosacea Awareness Month seeks to help identify patients who may otherwise ignore their warning signs.

As the next generation of students and residents begin their careers in dermatology, multimedia is helping deliver education in new engaging formats, from social networks to videos and podcasts.

New and emerging therapies such as biologics continue to improve quality of life and outcomes for patients with psoriasis. Biologics that block IL-23 functions present a unique opportunity to provide long-term, effective treatment.